To the Editor Dr Gage and colleagues1 found that genotype-guided warfarin dosing compared with clinically guided dosing reduced clinical events and improved anticoagulation control among patients undergoing hip or knee arthroplasty. I have a few concerns about the research and statistical methods.
First, the authors randomized patients receiving either hip or knee arthroplasty to genotype-guided or clinically guided warfarin dosing groups. However, patients receiving hip or knee arthroplasty should have been randomized separately and the end point calculations performed for 4 groups rather than 2.
Han-You X. Genotype vs Clinically Guided Dosing of Warfarin to Prevent Adverse Events. JAMA. 2018;319(12):1278–1279. doi:10.1001/jama.2018.0189
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: